VINCERX PHARMA INC (VINC) Stock Analyst Ratings
NASDAQ:VINC - Nasdaq - US92731L3042 - Common Stock - Currency: USD
ChartMill assigns a Buy % Consensus number of 83% to VINC. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 204. This target is 203900% above the current price.
VINC was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about VINC.
In the previous month the buy percentage consensus was at a similar level.
VINC was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-10-08 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2024-04-09 | Cantor Fitzgerald | Reiterate | Overweight |
| 2024-04-01 | Cantor Fitzgerald | Reiterate | Overweight |
| 2023-09-07 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2022-11-17 | Chardan Capital | Maintains | Buy |
| 2022-08-12 | SVB Leerink | Maintains | Outperform |
| 2022-06-08 | Cantor Fitzgerald | Maintains | Overweight |
| 2022-06-07 | Chardan Capital | Maintains | Buy |
| 2022-06-07 | B. Riley Securities | Maintains | Buy |
| 2022-06-07 | SVB Leerink | Maintains | Outperform |
| 2022-05-13 | Chardan Capital | Maintains | Buy |
| 2022-05-13 | SVB Leerink | Maintains | Outperform |
| 2022-01-14 | HC Wainwright & Co. | Initiate | Buy |
| 2021-12-23 | Cantor Fitzgerald | Initiate | Overweight |
| 2021-11-01 | SVB Leerink | Initiate | Outperform |
| 2021-09-13 | Laidlaw & Co. | Initiate | Buy |
| 2021-08-25 | B. Riley Securities | Initiate | Buy |
| 2021-08-13 | Chardan Capital | Maintains | Buy |